Annovis Bio fully enrolls pivotal Phase 3 Alzheimer's trial, exceeding targets, with data readouts set for 2027 and 2028
ANVS sits 29% above its 52-week low of $1.541.
Summary
Annovis Bio announced full enrollment of its pivotal Phase 3 Alzheimer's trial with 850 patients, exceeding targets. Symptomatic data is expected in Q1 2027, disease-modifying data in Q1 2028, with NDA submissions to follow each readout.
Key Events · Product Development and Regulatory · ANVS
-
Phase 3 Trial Fully Enrolled
The pivotal Phase 3 trial of buntanetap in early Alzheimer's disease reached full enrollment of 850 patients, exceeding original projections, across 83 U.S. clinical sites.
-
Dual Data Readouts Planned
A 6-month symptomatic analysis is expected in Q1 2027, and an 18-month disease-modifying analysis in Q1 2028, each designed to support a separate NDA submission.
-
Regulatory Pathway Advancing
The company has begun NDA preparations based on prior FDA guidance, positioning for submissions shortly after each readout.
-
Operational Execution De-Risks Pipeline
Rapid enrollment from 50 patients a year ago to 850 today demonstrates strong operational capability and patient/physician interest, critical for a company with a going-concern warning.
Analysis · ANVS · Life Sciences
Reaching full enrollment of 850 patients in the pivotal Phase 3 trial for buntanetap in early Alzheimer's disease marks a major de-risking event for Annovis Bio. The trial surpassed original enrollment projections, which strengthens its statistical power. With a going-concern warning and a recent $15M raise, the company's survival hinges on this trial. The dual-readout design—symptomatic data in Q1 2027 and disease-modifying data in Q1 2028—provides two near-term catalysts, each intended to support an NDA submission. This milestone keeps the company on track and validates operational execution, directly addressing the key risk that has weighed on the stock.
At the time of this filing, ANVS was trading at $1.98 on NYSE in the Life Sciences sector, with a market capitalization of approximately $83M. The 52-week trading range was $1.54 to $5.50. This filing was assessed with positive market sentiment and an importance score of 8 out of 10.